- Home
- ZGN vs BEAM Comparison
ZGN vs BEAM Comparison
Compare ZGN & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZGN
- BEAM
- Stock Information
- Founded
- ZGN 1910
- BEAM 2017
- Country
- ZGN Italy
- BEAM United States
- Employees
- ZGN N/A
- BEAM N/A
- Industry
- ZGN Apparel
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZGN Consumer Discretionary
- BEAM Health Care
- Exchange
- ZGN Nasdaq
- BEAM Nasdaq
- Market Cap
- ZGN 2.1B
- BEAM 2.3B
- IPO Year
- ZGN N/A
- BEAM 2020
- Fundamental
- Price
- ZGN $9.90
- BEAM $22.11
- Analyst Decision
- ZGN Buy
- BEAM Strong Buy
- Analyst Count
- ZGN 5
- BEAM 11
- Target Price
- ZGN $10.22
- BEAM $49.40
- AVG Volume (30 Days)
- ZGN 518.3K
- BEAM 2.3M
- Earning Date
- ZGN 09-05-2025
- BEAM 11-04-2025
- Dividend Yield
- ZGN 1.43%
- BEAM N/A
- EPS Growth
- ZGN N/A
- BEAM N/A
- EPS
- ZGN 0.43
- BEAM N/A
- Revenue
- ZGN $2,248,050,499.00
- BEAM $55,701,000.00
- Revenue This Year
- ZGN N/A
- BEAM N/A
- Revenue Next Year
- ZGN $4.55
- BEAM $19.01
- P/E Ratio
- ZGN $22.35
- BEAM N/A
- Revenue Growth
- ZGN N/A
- BEAM N/A
- 52 Week Low
- ZGN $6.05
- BEAM $13.53
- 52 Week High
- ZGN $10.70
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- ZGN 50.03
- BEAM 41.29
- Support Level
- ZGN $9.59
- BEAM $20.76
- Resistance Level
- ZGN $10.46
- BEAM $22.72
- Average True Range (ATR)
- ZGN 0.30
- BEAM 1.67
- MACD
- ZGN -0.06
- BEAM -0.28
- Stochastic Oscillator
- ZGN 40.91
- BEAM 23.66
About ZGN Ermenegildo Zegna N.V.
Ermenegildo Zegna NV designs creates, and distributes luxury menswear and accessories under the Zegna brand, as well as womenswear, menswear, and accessories under the Thom Browne brand. The company operates in three segments: the Zegna segment (comprising three product lines: Zegna Branded Products, Textile, and Third Party Brands); the Thom Browne segment, and the Tom Ford Fashion segment. The company generates the majority of its revenue from the Zegna segment.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.